Snapshot from Aug 25, 2026 at 07:00 UTC. For live data and tracking: View Live

United States & Canada — Health Canada

19 shared events · Importance 5 · Last updated Aug 11, 2026

Importance
5
Shared Events
19
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
63
Regulatory
United States: The United States is one of the initial markets where VueJect will be available following FDA clearance, potentially improving access to advanced cardiac imaging technology.
Canada — Health Canada: Canada — Health Canada authorized VueJect under Medical Device License No. 115637, permitting its sale in Canada.
Aug 11, 2026 · 7 articles
60
Business
United States: The United States' executive order prioritizing psychedelic therapies for accelerated FDA review and expanded patient access has intensified attention on ibogaine, creating a significant market opportunity.
Canada — Health Canada: Canada — Health Canada's regulation of ibogaine under the Food and Drugs Act and its listing on the Prescription Drug List provides a favorable regulatory environment for Optimi Health's operations.
Jun 08, 2026 · 14 articles
55
Tech
United States: The United States>>> was the location of the U.S.-led study of daraxonrasib and the initial application for drug licensing to the United States — Food and Drug Administration>>>.
Canada — Health Canada: Canada — Health Canada>>> has not yet received an application to license daraxonrasib in Canada>>>. Its role is to regulate and approve new drugs for use in the country, impacting the timeline for Canadian patient access.
May 29, 2026 · 74 articles
45
Business
United States: The United States is a target market for future clinical research involving Optimi Health's psilocybin product.
Canada — Health Canada: Canada — Health Canada issued the Drug Establishment Licence (DEL) to Optimi Health, authorizing the company's manufacturing, packaging, labeling, testing, storage, and distribution of controlled drug products.
Jun 02, 2026 · 25 articles
42
Business
United States: The US is part of North America, which held the largest market share in 2025, supported by strong regulatory frameworks and advanced manufacturing.
Canada — Health Canada: Canada — Health Canada provides supportive regulatory frameworks that facilitate product approvals and market growth in Canada.
Jul 28, 2026 · 6 articles
40
Business
United States: The standardized workflow in Canada for ClearPoint Neuro's system is already in use in the United States, allowing for consistency in clinical trials.
Canada — Health Canada: Canada — Health Canada granted the Medical Device License to ClearPoint Neuro for its Neuro Navigation System, facilitating its use in Canadian neurosurgery centers.
Apr 20, 2026 · 6 articles
40
Regulatory
United States: The U.S. is a target market where Diagnosis plans to submit CARA to the FDA; a legacy version is already cleared.
Canada — Health Canada: Canada — Health Canada granted a Class II medical device licence to Diagnosis for the CARA System, marking a regulatory approval.
Jul 27, 2026 · 6 articles
35
Business
United States: The United States is one of the countries where Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel has been evaluated in clinical trials and where additional regulatory filings are planned.
Canada — Health Canada: Canada — Health Canada is the regulatory body whose approval is required for Medexus Pharmaceuticals to begin commercializing Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel in Canada.
Jun 10, 2026 · 6 articles
32
Business
United States: The United States was the first market where WYNZORA was approved, but is not directly affected by this Canadian launch.
Canada — Health Canada: Canada — Health Canada approved WYNZORA in December 2025, a regulatory prerequisite for the launch.
Aug 20, 2026 · 6 articles
24
Business
United States: The United States is a key market for Kane's products, where commercial activities have commenced following FDA clearance.
Canada — Health Canada: Canada — Health Canada approval for Kane's products enables commercial sales in Canada, contributing to the company's market presence.
Aug 05, 2026 · 7 articles
24
Business
United States: Fluctuations in the United States contributed to a decrease in MedMira's loans in default.
Canada — Health Canada: Canada — Health Canada is the regulatory body providing initial feedback to MedMira regarding the approval process for its Multiplo Complete Syphilis Antibody Test.
Jun 30, 2026 · 6 articles
24
Business
United States: United States>>> is a key market for Diagnosis's CARA platform, with the company pursuing FDA clearance.
Canada — Health Canada: Diagnosis is pursuing regulatory clearance with Canada — Health Canada>>> for its CARA platform, a key milestone for market expansion in Canada.
Jun 05, 2026 · 11 articles
22
Regulatory
United States: The U.S. is the home country of the FDA; no direct impact from this announcement.
Canada — Health Canada: Canada — Health Canada provided scientific advice on the trial design, consistent with its regulatory role; no direct impact on the agency.
Jul 06, 2026 · 6 articles
10
Regulatory
United States: Spectral Medical obtained exclusive development and commercial rights for PMX in the United States.
Canada — Health Canada: Canada — Health Canada has licensed PMX for therapeutic use, indicating its approval in Canada.
Jun 25, 2026 · 6 articles
0
Regulatory
Canada — Health Canada: Canada — Health Canada issued a corresponding notice for the recall of Ryobi pressure washers in Canada, ensuring consumer safety in the region.
Aug 28, 2025 · 7 articles
0
Tech
Jan 16, 2026 · 23 articles
0
Regulatory
Canada — Health Canada: Canada — Health Canada is the regulatory body in Canada to which Diagnosis plans to submit CARA for approval, impacting its commercialization in Canada.
Apr 08, 2026 · 6 articles
0
Domestic
Canada — Health Canada: Canada — Health Canada is the government agency responsible for drug approval processes in Canada. Bill C-286 seeks to streamline its Special Access Program for psilocybin and psilocin, which has been criticized for slow and unpredictable approvals.
Jun 16, 2026 · 6 articles
0
Tech
Canada — Health Canada: Canada — Health Canada approved the urgent application for exosome therapy on compassionate grounds, allowing the world-first treatment to proceed.
Jun 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States and Canada — Health Canada interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.